Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) reports material definitive agreements entered into on April 10, 2020, with affiliates of The Blackstone Group Inc. The filing was submitted on April 13, 2020. The transactions involve a royalty purchase, a new debt facility, and an equity placement designed to strengthen the company's balance sheet and fund operations.
Key Financial Metrics and Transaction Details
Royalty Purchase
- Upfront Proceeds: $500.0 million received on the closing date.
- Future Proceeds: $500.0 million payable on September 30, 2021.
- Assets Sold: 50% of royalties on net sales of inclisiran (by The Medicines Company) and 75% of commercial milestone payments.
- Contingency: If royalty payments to Blackstone do not reach $1.0 billion by December 31, 2029, the royalty share sold increases to 55% effective January 1, 2030.
Debt Facility
- Total Facility Size: Up to $750.0 million senior secured delayed draw term loan.
- Tranche Structure:
- Tranche 1: $200.0 million (must be requested by December 31, 2020).
- Tranche 2: Up to $250.0 million (must be requested by June 30, 2021).
- Tranche 3: Up to $250.0 million (must be requested by December 31, 2021).
- Interest Rate: LIBOR + 7% or Base Rate + 6%, with floors of 1% and 2% respectively. Option to pay interest in kind (PIK) at +1% for the first three years.
- Fees: 2.5% funding fee on funded amounts; 1.0% exit fee on commitments.
- Collateral: Secured by intellectual property (ONPATTRO, GIVLAARI, vutrisiran), remaining inclisiran royalties, subsidiary equity, and cash/equipment.
- Liquidity Covenant: Must maintain consolidated liquidity of at least $100.0 million at the end of each fiscal quarter.
Equity Placement
- Shares Sold: 963,486 shares of common stock.
- Proceeds: $100.0 million.
- Price Per Share: $103.79 (30-day volume weighted average price).
Material Changes and Strategic Impact
The filing represents a significant capital raise totaling $1.3 billion in potential proceeds ($1.0 billion from royalty sale, $750 million debt facility, and $100 million equity, noting the debt is a delayed draw facility). The company has secured immediate liquidity of $600 million ($500 million royalty + $100 million equity) with the option to access up to $750 million in debt financing contingent on specific milestones or timeframes. This structure reduces immediate cash burn pressure while monetizing future revenue streams from inclisiran.
Guidance, Risks, and Covenants
- Debt Conditions: Tranche 2 and Tranche 3 funding is contingent on either the first U.S. sale of inclisiran or revenue from ONPATTRO and GIVLAARI reaching $300.0 million in a trailing twelve-month period. If not met by the initial deadlines, funding is possible until December 31, 2022.
- Restrictive Covenants: The Credit Agreement restricts the company's ability to incur additional debt, make acquisitions, pay dividends, or sell collateral assets without lender consent.
- Prepayment Penalties: Significant prepayment fees apply if the loan is repaid early (Make-whole before 2 years; 5% between 2-3 years; 2% between 3-4 years; 1% between 4-5 years).
- Default Risks: Events of default include nonpayment, covenant breaches, and failure to maintain the $100 million liquidity threshold.
Investor Verification Checklist
- Verify the exact timing of the Tranche 1 loan drawdown (required by Dec 31, 2020) and its impact on immediate cash flow.
- Monitor progress toward the $300 million revenue threshold or inclisiran U.S. launch to unlock Tranche 2 and 3 funding.
- Review the detailed Security and Pledge Agreement to understand the specific scope of intellectual property pledged as collateral.
- Assess the dilution impact of the 963,486 shares sold and the registration rights granted to Blackstone affiliates.
- Track the $100 million quarterly liquidity covenant to ensure compliance and avoid default.